Document Type

Report

Publication Date

7-1-2025

Comments

This article is the author’s final published version in JCRS Online Case Reports, Volume 13, 2025, Article number e00177.

The published version is available at https://doi.org/10.1097/j.jcro.0000000000000177. Copyright © 2025 The Author(s).

Abstract

To report the use of topical losartan as a potential treatment of acute bilateral central corneal stromal haze in a patient presenting with a syndrome resembling central toxic keratopathy (CTK).Patient and Clinical Findings:A 51-year-old man presented with clinically significant central corneal stromal haze bilaterally 6 days after a periorbital and facial contact dermatitis secondary to pesticide exposure. Uncorrected and corrected distance visual acuity (UDVA and CDVA) were 20/80 and 20/70 in the right eye, and 20/200- and 20/150+ in the left eye, respectively. After unsuccessful treatment with topical antivirals, antibiotics and corticosteroids, the patient started off-label treatment with topical losartan 0.8 mg/mL, administered 6 times per day.Diagnosis, Intervention, and Outcomes:2 weeks after initiation, and 4 weeks from first presentation, UDVA and CDVA improved to 20/40 and 20/20 in the right eye, and 20/40 and 20/20 in the left eye. Complete resolution of corneal haze was observed at the slitlamp and anterior segment optical coherence tomography, and major corneal surface regularization could be seen on corneal tomography.Conclusions:Topical losartan, a transforming growth factor-β inhibitor, shows promise as a treatment for acute central corneal stromal haze secondary to a CTK-like syndrome. This clinical experience suggests that topical losartan may serve as a novel therapeutic option for such cases, but further clinical studies are needed to optimize dosages and treatment durations

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English

Download

Share

COinS